Skip to main content
. Author manuscript; available in PMC: 2015 Aug 14.
Published in final edited form as: Cell. 2014 Aug 14;158(4):833–848. doi: 10.1016/j.cell.2014.06.029

Figure 4. LATS2 inhibits the proliferation of tetraploid cells by stabilizing p53 and inactivating YAP, and is triggered by reduced RhoA activity.

Figure 4

(A) Western blot of p53, LATS2, and active YAP (p-S127) levels in 2N and 4N cells transfected with the indicated siRNAs. (B) Representative images of 2N and 4N RPE-FUCCI cells overexpressing either empty-vector control (Control), YAP-WT, or YAP-S5A, with quantitation of the percentage of S/G2 cells for each condition shown on right (from one representative experiment). Scale bar, 100 µm. (C) Western blot analysis of p53 and LATS2 levels in 2N, 4N, and 40 ng/ml doxorubicin-treated 2N (2N +Dox) RPE-FUCCI cells transfected with the indicated siRNAs. (D) Co-immunoprecipitation of HA-tagged LATS2-WT and endogenous MDM2 from 2N and 4N RPE-1 cells using anti-HA antibodies (one of two independent experiments). (E) Western blot analysis and quantitation of pull-down assays to detect active RhoA relative to total RhoA in serum-starved, 2N, and 4N RPE-1 cells (n=4; *p < 0.0003, one sample t-test). (F) Top Row: 2N, 4N, and Evolved 4N RPE-1 cells labeled for actin (Life-Act, white) and DNA (blue) on a PAA hydrogel. Bottom Row: Images showing the force field corresponding to the upper cells. The size and color of the arrows correspond to traction force magnitude measured (in Pascals). Below: The average energy density generated by each cell. 2N and 4N data points are from 4 independent experiments; 4N Evolved data points are from 2 independent experiments; *p < 0.0001, unpaired t-test. Scale bar, 20 µm. (G) hMSCs grown in mixed differentiation medium and stained with Oil Red. A non-differentiated diploid hMSC (arrowhead) and a tetraploid adipocyte (arrow) are highlighted. Right: The percentage of diploid and binucleated tetraploid cells that differentiate into adipocytes (n=2 independent experiments). (H) The percentage of S/G2 tetraploid or doxorubicin-treated RPE-FUCCI cells ± induction of RhoA-WT, RhoA-Q61L, or empty-vector control (Control) for 20 h with the corresponding western blot analysis of Hippo pathway activation (n=3; *p < 0.005, unpaired t-test). All error bars represent mean ± SEM.